Douglas Reznick, MD

Medical Oncologist / Hematologist

Douglas Reznick, MD | Rocky Mountain Cancer Centers

Centennial

14000 E Arapahoe Rd, Suite 160
Centennial, Colorado 80112

303-805-7744

Request an Appointment


SECONDARY LOCATION(S)

Aurora

1700 S Potomac St
Aurora, Colorado 80012

303-418-7600

Request an Appointment

Englewood - Swedish Medical Center

499 E Hampden Ave, Suite 450
Englewood, Colorado 80113

303-740-8200

Request an Appointment

Littleton

22 W Dry Creek Circle
Littleton, Colorado 80120

303-730-4700

Request an Appointment

About Douglas Reznick, MD

Dr. Reznick is a board-certified medical oncologist who joined Rocky Mountain Cancer Centers in 2004 and has been caring for patients through their cancer diagnosis for over two decades. He specializes in thoracic (lung), head & neck, and skin cancers, as well as primary brain tumors and benign (non-cancerous) blood disorders.

Providing comprehensive cancer care to his patients is a top priority. He strongly believes in educating and collaborating with his patients regarding their diagnosis, prognosis, and treatment options so a collaborative plan of care is tailored to each patient. Testing his patients’ tumors for specific cancer markers is an integral part of their work up, which helps to determine the best treatment options available for them based on their cancer type – including the most up-to-date cancer therapies.

Dr. Reznick participates in several tumor boards, where he collaborates with other cancer specialists including surgeons, radiologists, pathologists, and radiation oncologists to provide a comprehensive, multi-disciplinary approach to their diagnostic work up and management, which further enhances their overall care and outcome. Dr. Reznick emphasizes the importance of participating in clinical research trials whenever possible to ensure his patients are receiving the most advanced, cutting edge treatment for their diagnosis.

Board Certifications

Medical Oncology

Clinical Care Expertise

  • Benign (Non-Cancerous) Hematology
  • Brain Cancers
    • Astrocytoma
    • Brain Metastases
    • Choroid Plexus Carcinoma
    • Craniopharyngioma
    • Embryonal Tumors
    • Ependymoma
    • Glioblastoma
    • Glioma
    • Medulloblastoma
    • Oligodendroglioma
  • Gynecologic Cancers
    • Cervical Cancer
      • Adenocarcinoma
      • Squamous Cell Carcinoma
    • Ovarian Cancer
      • Epithelial Tumors
      • Germ Cell Tumors
      • Stromal Tumors
    • Uterine Cancer
      • Endometrial Cancer
        • Adenocarcinomas
        • Adenosquamous Carcinoma
        • Endometrial Adenocarcinoma
        • Endometrioid Carcinoma
        • Serous Adenocarcinoma
        • Uterine Carcinosarcoma
      • Uterine Carcinosarcoma
        • Endometrial Stromal Sarcomas
        • Undifferentiated Sarcoma
        • Uterine Leiomyosarcoma
    • Vaginal Cancer
      • Vaginal Adenocarcinoma
      • Vaginal Melanoma
      • Vaginal Sarcoma
      • Vaginal Squamous Cell Carcinoma
    • Vulvar Cancer
      • Vulvar Melanoma
      • Vulvar Squamous Cell Carcinoma
  • Head and Neck Cancers
    • Floor of Mouth Cancer
    • Lip Cancer
    • Mouth Cancer
    • Salivary Gland Cancer
      • Parotid Tumors
    • Soft Palate Cancer
    • Throat Cancer
      • Glottic Cancer
      • Hypopharyngeal Cancer (Laryngopharyngeal Cancer)
      • Nasopharyngeal Cancer
      • Oropharyngeal Cancer
      • Subglottic Cancer
      • Supraglottic Cancer
    • Thyroid Cancer
      • Anaplastic Thyroid Cancer
      • Follicular Thyroid Cancer
      • Medullary Thyroid Cancer
      • Papillary Thyroid Cancer
    • Tongue Cancer
    • Tonsil Cancer
  • Lung Cancer
    • Non-Small Cell Lung Cancer
    • Small Cell Lung Cancer
  • Mesothelioma Cancer
  • Solid Tumors
  • Skin Cancer
    • Basal Cell Carcinoma
    • Melanoma
    • Squamous Cell Carcinoma
  • Skull Based Tumors
  • Thoracic Cancers

Education

Fellowship

Hematology & Medical Oncology, University of Colorado School of Medicine, Aurora, CO

Residency

Internal Medicine, Presbyterian St. Luke’s Medical Center, Denver, CO

Medical School

Sackler School of Medicine, New York State/American Program Center, Tel-Avivi, Israel

Patient Care Philosophy

When caring for individuals with cancer and blood disorders, the main focus tends to be on the treatment. However, it is equally important to address their emotional and spiritual needs. Giving patients, as well as their family members and friends, the time and education required to help navigate them through the experience is just as important. Paying close attention to one’s overall needs and well-being is my main priority when treating all patients.

Languages Spoken

  • English
  • French
  • Hebrew

Additional Information

Rocky Mountain Cancer Centers Partnership Board
US Oncology Research Committee

December 2020. Presenter, Lung Cancer Screening, Diagnosis and Treatment for the Primary Care Provider. Rocky Mountain Cancer Centers.

August 2018. Presenter, Transforming the treatment of NSCLC: Options for First Line Treatment of Metastatic EGFR Mutation-Positive and Immunotherapy for Stage III Unresectable Disease. ASCO Denver.

July 2018. Presenter, Addressing the Unmet Need for Patients with Unresectable Stage III Non-Small Cell Lung Cancer. 19th Annual International Lung Cancer Congress.

March 2018. Presenter, Addressing the Unmet Need in Patients with Non-Small Cell Lung Cancer: New Treatment Options for Unresectable Stage III Disease and Metastatic Epidermal growth factor receptor Mutation-Positive Disease. Hematology Oncology Pharmacy Association Annual Conference.

February 2018. Presenter, Immunotherapy for Patients with Unresectable Stage III Non-Small Cell Lung Cancer Following Chemoradiation Therapy. Sripps Clinic 38th Annual Conference: Clinical Hematology & Oncology.

November 2017. Presenter, Changing Landscape for Treatment of Metastatic Non-Small Cell Lung Cancer. US Oncology 16th Annual Science Forum.

September 2017. Presenter, A Treatment Option in the Management of Metastatic NSCLC and Certain Advanced Cancers.

March 2017. Presenter, A Treatment Option of Patients with Metastatic EGFR T790M Mutation-Positive NSCLC, as Detected by an FDA approved Test at Progression on or after EGFR – TKI therapy. Multi-Disciplinary Thoracic Oncology Symposium.